Metabolic adaptation of glucose-deprived macrophages involves partial gluconeogenesis
Abstract
Macrophages are recruited to sites of infection contributing to the killing of bacteria, but also to malignant tumors, where they promote angiogenesis and suppress antitumor immune responses. The metabolic microenvironment in tumors is frequently depleted of important nutrients such as glucose. Here, we investigated metabolic adaptation strategies of macrophages to glucose deprivation using stable isotopic tracing. Lactate production was decreased, potentially indicating a reduction of glycolysis. In contrast, the contribution of glutamine to the tricarboxylic acid cycle via α-ketoglutarate and reductive carboxylation were increased. Moreover, gluconeogenesis, the reverse pathway of glycolysis, was activated in glucose-deprived macrophages, proceeding partially to the generation of glycolytic intermediates and glycerol-3-phosphate. The partial gluconeogenesis pathway was abrogated in human and murine macrophages lacking the initial gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PCK2, mitochondrial isoform). Partial gluconeogenesis was higher in anti-inflammatory, interleukin-4-stimulated compared to proinflammatory, interferon-γ/lipopolysaccharide-stimulated macrophages. Single-cell analysis and immunostaining revealed expression of PCK2 in macrophages from both lung cancer and normal lung. Low glucose conditions only partially modulated macrophage phenotypes, leading to reduced CD80 surface marker levels in proinflammatory, and enhanced vascular endothelial growth factor expression in anti-inflammatory macrophages. Our study reveals partial gluconeogenesis in glucose-deprived macrophages and shows that this versatile type of immune cells exhibits remarkable metabolic flexibility.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (18)
Katharina Schindlmaier
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz
Theresa Haitzmann
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz
Visnja Bubalo
Division of Pulmonology, Department of Internal Medicine, Medical University of Graz
Barbara Konrad
Division of Pulmonology, Department of Internal Medicine, Medical University of Graz
Joseph Jelwan
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz
Gabriele Bluemel
Department of Biosciences and Medical Biology, Bioanalytical Research Labs, University of Salzburg
Sonja Rittchen
Division of Immunology, Otto Loewi Research Center, Medical University of Graz
Vanessa Jäger
Division of Oncology, Department of Internal Medicine, Medical University of Graz
Michael A. Dengler
Division of Oncology, Department of Internal Medicine, Medical University of Graz
Luka Brcic
Diagnostic and Research Institute of Pathology, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz
Jörg Lindenmann
Lung Research Cluster, Medical University of Graz
Leigh M. Marsh
Lung Research Cluster, Medical University of Graz
Thomas O. Eichmann
Core Facility Mass Spectrometry, Medical University of Graz
Alexander Kirchmair
Biocenter, Institute of Bioinformatics, Medical University of Innsbruck
Zlatko Trajanoski
Julia Kargl
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz
Cristina Muñoz-Pinedo
Preclinical and Experimental Research in Thoracic Tumors, Bellvitge Biomedical Research Institute
Katharina Leithner
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz